Issue of Equity & PDMR Notifications

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that it has raised £800,000 (the "Subscription") by way of an issue of 42,105,263 new ordinary shares of £0.0003 each ("Ordinary Shares") at a price of 1.9p per new Ordinary Share (the "Issue Price") by way of subscriptions ("Subscription Shares"), with each Subscription Share being accompanied by one warrant to subscribe for a new Ordinary Share.

The net proceeds from the Subscription are intended to support the advancement of Genflow's scientific programs and to provide sufficient cash runway, enabling the Company to engage in potential future licensing negotiations from a strong position.

Both Dr Eric Leire, Chief Executive Officer of the Company and Gad Berdugo, the newly appointed Chairman of the Company, have participated in the Subscription.

Subscribers in the Subscription have been issued with one warrant to subscribe for one new Ordinary Shares for every Subscription Share, with each Warrant entitling the holder to acquire one new Ordinary Share at the Issue Price at any time in the two-year period from issue (the "Warrants"). The Warrants will be in certificated form and none of the Warrants will be admitted to trading.

If exercised in full, the warrants would result in the issue of up to a further 42,105,263 ordinary shares and raise up to £800,000).

Admission, Conditionality and Total Voting Rights

Application will be made for the Subscription Shares to be admitted to trading ("Admission"). Admission is currently expected to become effective on or around 11 March 2026.

On Admission, the issued ordinary share capital of the Company will comprise 535,653,205 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, on Admission, the total number of Ordinary Shares and voting rights in the Company will be 535,653,205.

Following Admission, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

"This financing strengthens our balance sheet, supports continued execution across our key development programs, and provides sufficient cash runway to approach potential licensing negotiations from a capitalized position."

PDMR Notifications